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Artemisinin-Based Combination Therapy (ACTs) Drug Resistance Trends in  
 
Plasmodium falciparum Isolates in Southeast Asia 
 
 
 Jessica L. Schilke 
ABSTRACT 
 
Plasmodium falciparum, one of the parasites that cause clinical malaria, is a 
continuous public health concern, especially in Asia and Africa.  Unfortunately, the 
parasite has developed resistance to many drugs created to treat and prevent the disease.  
Artemisinin and its derivatives are the new gold standard for treatment of malaria, 
yet treatment failures in clinical studies are starting to be reported.  Clearly, artemisinin 
resistance needs to be characterized and dealt with accordingly.  In support of the Gates 
Foundation Artemisinin Consortium, we conducted a blinded study to elucidate the 
phenotypic response of artemisinin derivatives of parasites derived from patient blood 
samples from Cambodia and Thailand.  Blood samples containing Plasmodium 
falciparum were cultured and then assayed using SYBR green as an indicator to obtain 
drug IC50s.  The data suggested that many isolates are not demonstrating resistance to 
artemisinin.  However, a select few are showing some resistant characteristics in the form 
of elevated IC 50s, especially to some of the drugs already identified in previous studies 
as drugs having resistant characteristics. Compared to studies conducted within the past 
ten years, no significant changes in parasite susceptibility to the artemisinin drugs have 
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been observed.  Additional analysis of clinical outcomes, therapeutic drug levels, and 
molecular markers needs to be completed before it can be assumed that artemisinin 
resistance has emerged.
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Introduction 
Malaria  
Malaria is one of the most problematic tropical diseases worldwide.  Endemic to 
Parts of South and Central America, Africa, and Southeast Asia, half of the world is at 
risk for contracting malaria.  It’s responsible for over 300 million illnesses per year and 
an estimated three million mortalities (WHO, 2008). One malaria related death occurs 
approximately every 30 seconds, mainly in children and pregnant women.  Malaria is 
caused by a parasite in the genus Plasmodium, and five different species affecting 
humans have been discovered thus far.  Of those five species, Plasmodium falciparum by 
far causes the most morbidity and mortality.   There is no vaccine for malaria, but there 
are treatment options available.  Unfortunately, drug resistance has rapidly become a 
major issue in controlling malaria, and has been identified in both Plasmodium faciparum 
and Plasmodium vivax (CDC, 2008).  This thesis attempts to classify some of the 
resistance trends to some currently common treatment options in Southeast Asia, 
specifically in Thailand and Cambodia. 
Life Cycle 
The definitive host of the malaria parasite is the female anopheline mosquito 
(John, 2006).  The female mosquito takes a blood meal, and injects sporozoites located in 
her salivary glands into her host (see Figure 1).  These sporozoites then travel from the 
bloodstream to hepatocytes.  Asexual reproduction (schizogony) then occurs in the liver.  
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Schizogony occurs immediately in P. falciparum, and results in the formation of 
merozoites, which move into the blood stream due to the rupturing of hepatocytes.  The 
merozoites invade RBCs, and erythrocytic schizogony follow, producing anywhere from 
2 to 36 merozoites per infected red blood cell.  The erythrocyte eventually ruptures, 
releasing more merozoites into the blood stream. Usually after the patient becomes ill, 
some of the merozoites form male and female gametocytes, which can then be taken up 
by the mosquito during the blood meal process.  Once in the mosquito stomach, these 
gametocytes mature into micro and macrogametes.  The male microgamete is then 
capable of fertilizing the female macrogamete, which forms into an ookinate.  The 
ookinate then becomes an oocyst just outside of the mosquito’s stomach.  The oocyst 
produces sporozoites, which can detach and find their way into the salivary glands of the 
mosquito.  The sporozoites are then injected into the mosquito’s host when the female 
mosquito takes a blood meal.  This thesis examines the asexual erythrocytic stages of 
Plasmodium falciparum in vitro under drug pressure. 
Clinical features 
Plasmodium falciparum is the malaria species that causes the most morbidity and 
mortality in humans.  The incubation period in the body is the shortest, only about 8-11 
days, and if left untreated, could last anywhere from 6-17 months.  Fever in P. falciparum 
can be ‘continuous, remittent or quotidian” (John, 2006). Prodromal symptoms include 
aches and pains, photophobia, nausea and even vomiting.  The paroxysm stage begins 
with the symptoms of feeling severely cold, even though fever is present.  Ten to fifteen 
minutes later, the patient begins to feels extremely warm and becomes flushed and 
agitated.  Restlessness and delirium can also accompany this stage.  This can last hours 
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and is followed by a sweating phase.  The paroxysm stage in P. falciparum patients can 
occur mere hours after the previous episode.  Other symptoms include splenomegaly, 
anemia, capillary obstruction, decreased blood flow, hypoxia, renal failure and even 
death in cases of cerebral malaria. 
 Blackwater fever is yet another complication of P. falciparum, which occurs from 
severe hemolysis within the patient’s veins and is usually associated with the use of 
quinine (Rieckmann, 2006).  Other less common complications include Dysenteric 
Malaria, Algid Malaria, Pulmonary Edema, Tropical Splenomegaly Syndrome and 
Hypoglycemia.  Pathogenesis in humans is caused by a variety of factors, including 
hemolysis of red blood cells, red blood cells sticking to the endothelial cells of the 
vascular system and decreasing blood flow, the patient’s own immune response, parasite 
metabolites released into the body, as well as the malaria pigment (Rieckman, 2006). 
Artemisinin 
Artemisinin is a lactone derived from the leaves of Artemisia annua, or sweet 
wormwood.  It is also known to the Chinese as qinghao, and has been used to treat 
ailments such as hemorrhoids and fever for over a thousand years.  China’s government 
later decided to try to join traditional Chinese medicine with western medicine, and a 
program to screen traditional Chinese remedies for activity began in 1967.   
It was first proposed that the mechanism of action of artemisinin was due to the 
endoperoxide bridge, which generates free radicals. It has been thought that the malaria 
parasite has been susceptible to free radicals.  To test the theory that free radicals were 
involved in the mechanism of action, tests were conducted in the 1980s and it is was 
found that free radical generators promoted the activity of artemisinin against malaria, 
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and free radical scavengers were found to inhibit the activity. Free radicals were also 
found to inhibit a calcium adenosine triphoshatase PfATPase 6 (Sherman, 1998). 
Artemisinin is active against the blood schizont stage of the malaria parasite, and reduces 
parasite load in all malaria species.    It is unique in that it is effective in killing all 
asexual blood stages of the malaria parasite as well as gametocytes in P. falciparum.  
Before artemisinin was discovered, the only drug that killed gametocytes was 
primaquine. The highest drug concentrations in the plasma occur around 3 hours when 
administered orally, and around 11 hours when given in a suppository form.  It has a 
molecular weight of 282.3; the elimination half life is around 1 hour.  Finally, it is 
converted into inactive metabolites via enzymes including cytochrome P450 and 
CYP2B6.   
 Side effects include dizziness, gastrointestinal problems, reticulocytopenia, 
neutropenia, and infrequently electrocardiographic abnormalities. However, the 
artemisinin drugs do not cause nearly as many side effects in humans as some of the other 
antimalarials, and there are currently no known drug interactions, making it an almost 
ideal treatment option.  One in 3000 patients report hypersensitivity reactions, which is 
the only serious side effect reported. 
 The recommended use of artemisinin, as well its derivatives, artemether, 
artemotil, artelinic acid, dihydroartemisinin, artemether and artesunate, is in combination 
with other antimalarials in order to reduce the potential emergence of resistance (WHO, 
2006).  
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Artemether 
The methyl ether form of dihydroartemisinin is artemether.  With a molecular 
weight of 298.4, peak concentrations of drug in the plasma occur around two to three 
hours after it is taken orally.  It can also be introduced into the body by being injected 
directly into the muscle of the patient, but this method causes extreme variability in 
absorption amount, with peak times ranging from 6 to over 18 hours.  However, when 
injected, artemether itself is the predominate form of the drug, whereas when 
administered orally, dihydroartemisinin is the artemisinin derivative found most readily 
throughout the body.  The elimination half life is about 1 hour when given orally but can 
be longer when injected.  Biotransformation occurs via CYP3A4, a cytochrome p40 
enzyme. 
 Side effects are very similar to artemisinin, however, it was found in animals to 
cause damage to the neurons when given intramuscularly.  This is due to the fact that 
high concentrations of drug are within the blood when given in this manner.  There are 
also no known drug interactions with artemether.  
Artesunate 
 The sodium salt of the hemisuccinate ester of artemisinin is artesunate.  It is water 
soluble, and can be administered orally, intravenously, as well as rectally.  Peak plasma 
levels happen at around 1.5 hours after oral administration, 2 hours after given rectally, 
and one half hour after given intramuscularly.  The form found most frequently in the 
body is dihydroartemisinin.  Toxicity is again similar to artemisinin, and there are no 
currently known drug interactions. 
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Dihydroartemisinin 
 An active metabolite of artemisinin is known as dihydroartemisinin.  It can be 
given both in oral and rectal forms, and its effectiveness can be compared to oral 
administration of artesunate.  Peak plasma levels occur at around 2.5 hours when given 
orally, and slightly slower (around four hours) when given rectally.  Toxicity is similar to 
that of artemisinin and there are no currently known drug interactions. 
Artemisinin Combination Drugs (ACTs) 
Lumefantrine 
Lumefantrine is a drug that is co administered orally with artemether.  It needs to 
be consumed with fatty foods which increases absorption by 108%.  Highest levels in the 
plasma occur at around 10 hours after administering.  There is no toxicity reported with 
lumefantrine, and the only side effects reported include headache, dizziness, nausea, and 
discomfort of the abdomen. It has a molecular weight of 528.9. 
Atovaquone 
Atovaquone is a drug that is known to interfere with the electron transport chain 
of the parasite.  It is effective against all Plasmodium species, and also inhibits oocyst 
development within the mosquito, as well as development in the liver before it invades 
red blood cells.  It is has been available since the early 1990s in combination with 
proguanil in tablet form (Malarone).  Similar to lumefantrine, absorption is increased 
when taken with food.  The half life is around 66-70 hours due to enter hepatic recycling, 
however pregnancy can reduce its half life.   
Mild side effects reported include diarrhea, vomiting, insomnia, skin rash, fever, 
increased liver enzymes, and sometimes anemia and neutropenia.  When administered to 
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patients taking drugs such as tetracycline, metoclopramide, as well as benzodiazepines, 
cephalosporins, laxatives, opiods and paracetamol, reduced concentrations in the plasma 
may occur.  It also decreases metabolism of the drugs zidovudine and cotrimoxazole.  
Atovaquone/proguanil (Malarone) is usually successful after a three day course, however 
it is not widely used due it its high costs. (Rieckman, 2008).  It can also be used as a 
prophylactic for travelers and military personnel. Malarone is also used to treat travelers 
not endemic to malarias areas, and is approved for use in North America and Europe 
(CDC, 2008). Studies examining patient isolates along the Thai-Myanmar and Thai-
Cambodia border have shown that resistance to atovaquone is not yet an issue.  It has, 
however, been reported that the point mutation on codon 268 on the cytochrome B gene 
is responsible for treatment failures that have thus far been reported (Khositnithikul, 
2008).  This point mutation is key in identifying atovaquone resistant blood isolates. 
Mefloquine 
Mefloquine is effective against all Plasmodium species and came about as a result 
of screening a massive amount of drugs for antimalarial activity during the 1960s 
(Reichmann, 2008).  It is a 4-methanolquinoline related to quinine, and is given orally as 
the hydrochloride salt.  It is given both as a prophylactic to travelers, as well as a disease 
treatment.  It is only slightly water soluble, but is completely soluble in alcohol.  Since 
mefloquine has varying time to achieve peak levels in the plasma, it is administered in 
two separate oral doses 6-24 hours apart in order to improve absorption.  Enterohepatic 
recycling occurs with mefloquine.  It can be co administered with artesunate, which 
increases concentrations in the blood.  Unfortunately, side effects are common, including 
nausea vomiting diarrhea anorexia, abdominal pain, headache, dizziness, dysphoria and 
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various sleep disturbances such as insomnia and strange dreams. Less commonly, 
seizures, encephalopathy and psychosis can occur, as well as the occasional case of hair 
loss, skin rash, purities, muscle weakness and problems with liver function.  Some 
cardiovascular effects have also occurred when mefloquine was given.  There are also 
possible risks of drug interactions.  These include arrhythmias when taken with beta 
blockers, calcium channel blockers, amiodarone, pimozide, digoxin or antidepressants.  
When taken with chloroquine or quinine, convulsion risk is possible as well.  In order to 
minimize recrudescence and due it its low half life and ability to clear parasites, 
mefloquine is given in combination with artesunate.  Unfortunately, some cross 
resistance between mefloquine and artesunate has been reported in Thailand, as well as 
mefloquine resistance (Wongsrichanalai, 1999).  Researchers have identified an 
amplification of the gene pfmdr1 that has been linked to mefloquine resistance (Price, 
2004). 
Piperiquine 
 Piperiquine, otherwise known as bischloroquine, is given in combination with 
dihydroartemisinin to treat uncomplicated malaria.  Piperiquine has a long half life, so it 
not only able to treat uncomplicated malaria, but also to provide protection for 
reoccurrence.  The side effects are minimal, and the combination drug is inexpensive to 
dispense. (Tran, 2004) 
Anti-malarial Drug Resistance Patterns 
Most of the drug resistance towards anti-malarials was first documented and 
reported along the south-eastern border of Thailand and Cambodia.  For example, 
resistance began here in the 1950s to chloroquine, followed by the anti-malarials 
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sulfadoxine-pyrimethamine and mefloquine.  This is why the isolates collected were 
chosen from this location.  Drugs that were once “gold standards” to effectively treat 
patients infected with malaria are now almost completely ineffective, the origins of 
resistance being in Southeast Asia.   Therefore, newer drug classes are being developed in 
order to stay one step ahead of the parasite.  
The World Health Organization has made ACTs the most widely used and 
effective drugs worldwide (CDC.gov).  A drug combination of mefloquine and artesunate 
has replaced all previous drugs and been the main treatment prescribed ever since 1995.  
However recently, failure rates with artemisinin drugs in the clinic have been reported, 
specifically along the Thai-Cambodian border.  If resistance truly is occurring, control 
measures must be started in order to characterize and contain the resistance so that it does 
not become widespread, as in the case of past gold standard malarial treatments. 
 First, it is important to discern between drug resistance and “treatment failure”.  
Drug resistance is defined as “the ability of a parasite strain to survive, and/or multiply 
despite the proper administration and absorption of an antimalarial drug in the dose 
normally recommended” (Sherman, 1998).  Treatment failure, on the other hand, is 
“failure to clear malarial parasitemia and/or resolve clinical symptoms despite the 
administration of antimalarials (Sherman, 1998).  It also needs to be understood that drug 
resistance can indeed lead to treatment failure.  However, treatment failures can be 
caused by phenomenons other than drug resistance, including administering the incorrect 
dose and/or drug, compliance, drug quality not being up to standards, drug-drug 
interactions, issues with absorption of the drug, and incorrect diagnoses.  In order to 
combat some of these issues with malaria treatment that could lead to failure and possibly 
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resistance, the “Roll Back Malaria” strategy has been created in order to enforce proper 
compliance with treatment (Ikeoluwapo, 2008).  At least 18 countries in Africa have 
adopted this strategy, and 44 countries in Africa are now using artemisinin combination 
therapies (ACTs) as a first choice to treat uncomplicated malaria.  Enforcing proper use 
of ACTs isn’t as much of an issue in healthcare facilities as it is on a community level, 
which facilities drug failure and resistance.  Counterfeit treatments which do not contain 
the correct dose also tend to leak into communities, facilitating resistance. 
 Drug resistant malaria strains can arise in a variety of ways.  The first event 
leading to resistance involves a change in the parasites genetic code, following by a 
process of selection that allows the new resistance mutants to survive and take over as the 
dominant parasite (Sherman, 2008).  Factors that assist in resistance development include 
the amount of genetic mutations that are occurring in a certain region and the number of 
parasites that are exposed to the drug.  In addition, the amount of immunity in an 
individual with the disease under drug pressure and the pharmacokinetics are also 
involved in resistance (Sherman, 2008).  Therefore, it is imperative to administer the 
correct amount of drug needed to kill the parasite, so that the strongest parasites aren’t the 
only ones that survive and multiply.  Again, antimalarial drug distribution and dosing 
isn’t always properly regimented in some areas of the world.  Thus, these issues 
commonly arise.  Since lumefantrine, atovaquone and mefloquine are absorbed at varying 
rates due to their lipophilic properties, they are more prone to resistance, since the peak 
drug concentrations rely heavily on absorption. 
   Unfortunately, for reasons still unknown, one of the main issues with the 
artemisinin drugs is the tendency for patients to recrudesce (Giao, 2001).  One to four 
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weeks after being treated with an artemisinin drug, 10%-40% of patients experience 
recrudescence.  Parasites can become undetectable after a single day of artemisinin 
therapy, but patients can recrudesce if not repeated treated.  One attempt to decrease the 
risk for resistance includes giving antimalarials in combination forms.  The hope here is 
that the drugs have unique mechanisms of actions and therefore the way that resistance 
would arise would vary.  This issue of recrudescence is also cause for alarm when 
looking at ACT resistance rates, and discerning between the recrudescent infections of P. 
falciparum and actual resistant strains.  In addition, the short half life of artemisinin 
makes it more difficult to monitor proper administration of the drug to patients, which 
could also lead to more unclassified resistance.  All of these issues combined could 
possible lead to widespread artemisinin resistance.  
ACT resistance studies 
Due to the unusually high incidence of drug resistance in Thailand and Cambodia, 
and some high clearance and treatment failure rates that were being clinically reported 
with some ACT use, studies were conducted to examine patient susceptibility to current 
ACTs.  The Army component of the U.S. Armed Forces Research Institute of Medical 
Sciences conducted two studies in 2005 and 2006 to determine if drug resistance was the 
culprit to these clinical failures. The first studies led to a conclusion that 16.6% of 
patients failed therapy when given a drug combination of mefloquine and artesunate 
(Penh, 2007).  A second study was then conducted administering artesunate alone.  In 
vitro results showed artemisinin IC50s were higher along the Thai-Cambodian border, 
versus other areas where the same treatment was administered.  A conclusion was made 
that preliminary evidence had been gathered that artemisinin resistance had emerged 
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along the Thai-Cambodian border.  Recently, another study was published in the New 
England Journal of Medicine that revealed out of 60 people receiving artesunate 
treatment, two were classified as having an artemisinin resistant infection (Noedl, 2008).  
Although this is a small amount of people, it is still concerning, as resistance can spread 
rapidly if not contained.  The most concerning data from this study was the prolonged 
clearance times for parasitemia, which significantly increased for all previous studies of 
ACTs.   
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Purpose 
The purpose of this thesis was to culture and then conduct blinded phenotypic 
analyses to identify possible ACT susceptibility trends in isolates infected with 
Plasmodium faciparum from regions in both Thailand and Cambodia.  These trends were 
observed both for single drugs, as well as in combination form.  Plasmodium falciparum 
isolates also were cultured and frozen for use in future ACT resistance experiments.  
Characterization of drug resistance is key in order to control the spread of the disease, 
containment of resistance, as well as successful treatment of the malaria parasite. 
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Figure 1: Life Cycle of Plasmodium falciparum 
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Figure 2: Chemical Structures of the 8 Compounds Tested 
Atovaquone                                         Artemisinin 
                                                                    Artesunate
Lumefantrine                                            Artemether     
                                             
Piperaquine                                                                                  Dihydroartemisinin 
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Methods 
Obtaining samples 
Isolate samples were collected from both Maesod in Thailand and Palan on the 
Thai-Cambodian border, cryopreserved and shipped to the University of South Florida in 
Tampa.  Reference strains C2B, W2 and D6 were used in this experiment in order to 
compare the blind isolate data. C2B is a P. falciparum strain that is resistant to 
atovaquone, due to a point mutation in cytochrome B.  W2, a strain isolated from 
IndoChina, is historically chloroquine resistant and mefloquine sensitive.  Lastly D6, a 
strain isolated from Sierra Leonne, is historically chloroquine sensitive and naturally 
mefloquine resistant. 
Thawing of Field Isolate Samples 
Each blood sample vial was wiped down with 70% Ethanol to sterilize, and then 
thawed in a 37°C water bath for 2 minutes.  The sample was then transferred into a 50 ml 
sterile centrifuge tube and 0.1% of 12% sterile NaCl of the volume of the isolate sample 
was added drop wise to the sample, swirling the sample between each drop addition.  The 
sample containing the 12% NaCl was then allowed to sit untouched for five minutes, 
followed by the addition of ten times of 1.6% sterile NaCl of the new isolate volume 
(isolate plus volume of 12% NaCl added).  The NaCl was added drop wise for the first ml 
with swirling between each drop, followed by swirling after each 0.5 ml addition of 1.6% 
NaCl.  The sample was then centrifuged at 4,000 rpm at 4°C for 2 minutes.  Next, the 
supernatant was aspirated off of the isolate, leaving a small amount above the hematocrit, 
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with taken not to remove any parasites.  The pellet was then resuspended in 10 ml of 
RMPI with HEPES, and centrifuged again at 4,000 rpm at 4° C for 2 minutes.  The 
supernatant was aspirated, again leaving a small amount above the pellet, then re-
suspended in 10ml of complete media containing 15% heat-inactivated AB plasma.  In 
the third round of isolate thawing, the complete media was supplemented with 10ul/1ml 
of penicillin/neomycin/streptomycin solution in order to reduce bacterial contamination.    
The suspension was then centrifuged at 4,000 rpm at 4° C for 2 minutes, and the 
supernatant removed once more as noted previously.  The pellet was then resuspended in 
10 ml RPMI with HEPES, and again centrifuged at 4,000 rpm at 4°C for 2 minutes.  The 
supernatant was aspirated again, and the pellet resuspended in 2ml of complete media 
containing 15% AB plasma.  50ul of the suspension was added drop wise to filter paper 
and left to air dry for future studies of molecular markers.  If red blood cell lyses was 
observed, 15-30 ul of 50% hematocrit O (+) blood was added to the suspension prior to 
incubating the culture.  The suspension was then transferred into a six well plate, placed 
in a modulator incubator, air displaced with mixed gas (5%O2/5%CO2/90%N), and 
incubated at 37° C. 
Culturing  
Incubator modulators containing the six-well plates were gassed every twenty 
four hours with mixed gas.  Twenty four hours after initially thawing the isolates, the six-
well plate was removed from the incubator and tipped at a 45° angle to allow the 
hematocrit to settle in order to make slides.  5ul of hematocrit was removed to make both 
a thin and thick smear. Slides were made initially every day to check for growth of both 
the parasite and contamination.  O+ blood was continuously added to each well to keep 
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the isolate up to 4% hematocrit while in the six-well plates.  Contamination was 
contained by spinning the isolate in a 15 ml falcon tube at  4,000 rpm at 4° C for 2 
minutes, followed by removing the supernatant.  The remaining pellet was then 
resuspended in 2 ml fresh complete media containing 15% AB plasma, as well as 
penicillin/streptomycin/neomycin [5,000U/5mg/10mg] at a concentration of 2ul/ml. Each 
isolate was treated every day until contamination was no longer seen in the thick smear. 
 Slides were made less frequently (every 2-4 days) when no initial parasites were 
observed.  When 2% parasitemia was observed in an isolate thin smear, the isolate was 
centrifuged for 2 minutes at 37° C at 4000 rpm, and the old media removed.  The parasite 
was then resuspended in 5 ml 10% CM at 4% hematocrit (O+ blood) and transferred into 
a  tissue culture flask.  The flask was then incubated at 37° C with the carbon dioxide, 
nitrogen and oxygen mixture used previously.  Media was replaced with fresh 10% AB 
plasma every day, and both thin and thick smears were made, until the parasitemia 
reached 3%, and at least 40% ring stage was observed.  The flask was then split into two, 
and the remaining blood pellet was frozen down for stock.  These flasks were then 
checked every day until 3% parasitemia was observed.  At this point one flask was split 
again to continue growth, and the other flask was used for the drug assay.  At least four 
cryopreserved vials of each isolate were frozen in total for stock and future use. 
Freezing Protocol 
 When the isolate was at least 40% rings and 3% parasitemia, they were frozen for 
future ACT resistance characterization studies.  The culture was centrifuged at 4,000 rpm 
for 15 minutes at 4°C, and the supernatant removed.  Glycerolyte 57 (57g glycerin, 1.6 g 
sodium lactate, 30 mg potassium chloride, buffered with 51.7 mg monobasic sodium 
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phosphate and 124,2 dibasic sodium phosphate, pH 6.8.) was added slowly drop wise to 
the pellet at 0.33 times that volume of the isolate pellet.  The sample was then allowed to 
stand for five minutes, and Glycerolyte 57 was added again drop wise at 1.33 times the 
volume of the original isolate pellet and the first Glycerolyte 57 addition.  The sample 
was then transferred into a cryovial and stored at -80° C for future resistance 
experiments.  
Plasma, Media, and Blood Preparation 
O+ RBCs were used when culturing and assaying each isolate.  Blood was 
suspended in RPMI 1640 plus HEPES containing sodium bicarbonate, and centrifuged at 
4000 g, 37° C for 15 minutes.  The supernatant and buffy coat were removed, and the 
remaining blood was re-suspended in the (RPMI/HEPES/sodium bicarbonate) wash and 
centrifuged three more times.  The supernatant was removed in between each wash and 
the blood was resuspended in RPMI wash media, at five, five, and fifteen minute 
increments.  After the supernatant was removed the final time, the remaining hematocrit 
was diluted to 50% in the RBC wash media, and stored at -40° C for up to one week 
before new 50% hematocrit was prepared. 
 Plasma for cell culture media was provided by Interstate Blood Bank.  Plasma 
was allowed to warm to 60° C for one hour with gentle agitation.  The plasma was then 
cooled at room temperature for 15 minutes, then refrigerated at -40°C for an additional 15 
minutes.  Plasma was then transferred into 50 ml falcon tubes, and centrifuged for 15 
minutes, at 4000 rpm for 15 minutes.  The plasma lots were then pooled and frozen at -
80° C.  Before use, plasma was thawed in a 37° C water bath. 
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Slide Preparation 
 A 5ul aliquot of the isolate sample was taken from culture, and 1ul was dispensed 
by smearing in a circler fashion on one part of the slide for the “thick smear,” and the 
remaining 4ul was dispensed on the other side of the slide for the thin smear.  A separate 
clean slide was used to spread a thin layer of cells across the second half of the slide.  The 
sample was allowed to dry, and the “thin smear” was dipped in methanol and again 
allowed to dry.  15% or 20% Giemsa stain was then dropped onto the slide, and the slides 
were then rinsed with water after a period of 10-20 minutes.  The slides were then dried 
and ready to be examined. 
Drug Assay Preparations 
Drug “mother” plates were prepared using the Biomek 3000 robot.  Drugs in the 
mother plates were all prepared at 10 times the final concentration to be used in the final 
assay “daughter” plate.  Initially, drug stock solution was prepared at a concentration of 1 
mg/ml and dissolved in DMSO.  Next, drugs were diluted down to ten times the desired 
concentration in 10%  AB plasma complete media, and 300 ul of each suspension was 
added to the first row of a 96 well mother plate.  The drugs then underwent a 1:2 dilution 
scheme to complete the “mother plate.”  This plate was used up to 5 times to make the 
‘daughter plates”, which contained both the drug as well as the parasites.  This dilution 
scheme reduced the final DMSO concentration to less than 1%.    
 Isolate Suspension for Assay: 
Once each isolate was grown to a least 3% parasitemia, and greater than 40% 
rings, each isolate culture was prepared for the drug assay.  First, the cells were 
centrifuged at 4000 g at 37° C for 5 minutes.  Complete media containing 10% AB 
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plasma was prepared, and 1.5% total hematocrit was added to the media, with a 
parasitemia of 0.5%.  The suspension was gently mixed before added to the daughter 
assay plate.  15 ul of the “mother plate” drug suspensions was transferred to each 
corresponding “daughter” well by the Biomek robot, and 150 ul of cell suspension was 
then added to each well. 25 mg/ml of each artemisinin and dihydroartemisinin were 
added directly  in duplicate form to serve as negative controls.  The parasite suspension 
without the addition of any drug served as the positive controls in the plate.  Finally, the 
plates were placed in a modulator incubator and  incubated for 72 hours at 37° C.  The 
incubator was gassed every 24 hours (5%O2/5%CO2/90%N).  After 72 hours, plates 
were wrapped in foil to protect from light, and placed in a -80°C freezer until the SYBR 
green assay was ready to be performed. 
SYBR Green Assay 
Drug plates containing lysed isolates were assayed via a fluorescent based SYBR 
Green assay, a quick and easier method of finding the IC50 values than alternate 
methods. (Bacon, 2006)  Plates were thawed for two hours after being frozen in a -80° C 
freezer overnight.  Then,100 ul of parasite suspension was transferred into a black 96 
well plate compatible with the plate reader.  The 100 ul of SYBR Green I in lyses buffer 
containing Tris 20 nM (Ph 7.5), EDTA (5mM), saponin (0.008% wt/vol and Triton X-
100 (0.08% wt/vol) was also added to the wells containing the thawed parasites in the 
drug assay plate.  The plates were then immediately allowed to incubate light free for one 
hour before read.  The intensity of the florescence was measured using the SpectraMax-
M2 plate reader, with an excitation wavelength of 485 nm and an emission wavelength of 
535 nm. 
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Isobologram Assay  
Three isolates that showed the highest resistance to the 8 compounds overall were 
chosen to perform a drug combination assay.  Starting plate concentrations for each drug 
were calculated by using the IC50 value calculated in the single compound assay.  The 
starting drug  IC50s were chosen in order for the IC50s in the multi drug plate to 
hypothetically be the original starting concentration in the plate if the assay was redone.  
The plate design consisted of a row of each of the drug pairs alone, followed by the pairs 
in ratios on 1:3, 1:1 and 3:1. The drug pairs tested consisted of either QHS or DHA, 
depending on which one the isolate was showing the least susceptibility to.  These drugs 
were paired with MFQ and PIP, both commonly administered drug combinations in the 
clinic. 
 Thai isolate 18, 6, and Cambodia isolate 6 were used in the isobologram assay 
plates.  W2 was used as a control.  The starting concentrations in the assay plate of Thai 
18 were 8.7 ng/ml for DHA, 234.2 ng/ml for MFQ and 179.9 ng/ml for PIP. Thai 6 had 
starting drug concentrations of  80 ng/ml for QHS, 175.1 ng/ml for MFQ, and 163.9 
ng/ml for PIP.  Cambodia isolate 6 had starting concentrations of 6.1 ng/ml for QHS, 56 
ng/ml for MFQ and 12.36 ng/ml for PIP.  Reference clone W2 had a starting 
concentration of 11.88 ng/ml for QHS, 30.22 ng/ml for MFQ, 225.25 ng/ml for PIP and 
4.9 ng/ml for DHA.   
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Data Analysis 
Linear and non-linear regression curves for IC50s, IC90s and FIC isobologram 
curves were calculating using DatAspects Plate Manager (DPM) software.  Data was 
imported into the software from the plate reader using the Biotec format.  Relative 
Fluorescent Units (RFUs) were converted into percent inhibition in the program. 
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Figure 3: Map Depicting Isolate Collection Sites 
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Figure 4: 6 Well Plates Containing Isolates  
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Figure 5:  Isolates Growing Within Tissue Culture Flasks 
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Figure 6  :  Geimsa Staining of Isolates  
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7:  96 Well Drug Assay Plate Set Up 
rug Name and Concentration in ng/ml) 
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Figure 8: Biomek 3000 “Robot” Used to Complete Drug Assays 
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Figure 9: Plate Reader for SYBR Green Assay 
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Figure 10:  Incubator Modulators Containing 6 Well Plates (Right) and 96 
Well Assay Plates (Left) 
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Results 
Cell Culture Success 
              A total of 66 isolates, 42 Cambodia, 24 Thai, were thawed.  Out of the 42 
Cambodia isolates, 19 grew enough to be assayed (45%).  Out of the 24 Thai isolates 
thawed, 15 grow well enough to be assayed (63%).  Overall, a growth success rate of 
52% was obtained.  The addition of antibiotic to the complete media during the thawing 
process noticeably increased the percentage of isolates that successfully grew.  For 
instance, a 50% growth success rate was obtained before the antibiotic was added during 
the thawing process, and a 56% growth rate was obtained after the antibiotic was added.  
Contamination was also greatly reduced overall when the antibiotic was added during the 
thawing process. Before antibiotic was added, at least 50% of samples showed some 
degree of bacterial contamination, both rods and cocci, versus around 5% after antibiotic 
was added. 
Single Drug Assay Data 
     The IC50s (in nmol/l) varied between isolates, depending on type of drug pressure 
(refer to tables 1 and 2, as well as Appendix B).  IC50s of isolates exposed to artemether 
ranged from 0.7 to 10.3 nmol/l.  IC50s of isolates exposed to artesunate ranged from 0.2 
to 6.4 nmol/l. IC50s of isolates exposed to atovaquone ranged from 0.2 to 13.9 nmol/l.  
IC50s of isolates exposed to dihydroartemisinin ranged from 0.4 to 7.1 nmol/l. IC50s of 
isolates exposed to lumefantrine ranged from 6.5 to 395.3nmol/l.  IC50s of isolates 
exposed to mefloquine ranged from 2 to 135.1 nmol/l. IC50s of exposed to piperaquine 
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ranged from 4.7 to 124.1 nmol/l.  IC50s of isolates exposed to Artemisinin ranged from 
1.4 to 35.4nmol/l.  
          Certain isolates, both Thai and Cambodian, consistently produced high IC50s in 
the standard 72 hours drug assay.  For instance, Cambodia isolate “6” produced some of 
the highest overall IC50s to artemisinin, artemether, lumefantrine, dihydroartemisinin, 
and mefloquine.  Thai isolate “6” was also consistently less susceptible to a majority of 
the drugs tested.  Cambodia isolate “5” was among the most susceptible parasites and 
produced the lowest IC50s to the drugs tested.  In addition, when observing IC50 trends 
in reference to MFQ, none of the 7 drugs showed a significant positive correlation in 
IC50 trends.   
Isobologram Assay Data 
          Thai isolate 6, Cambodia isolate 6, and Thai isolate 18 were chosen for the drug 
combination studies based on the fact that they showed the most evidence of resistance to 
the drugs when tested individually.  Isobolograms depicting the fractional inhibitory 
concentrations (FIC) curves were produced using the DPM software (refer to Appx. A).   
In order for a drug pair to be considered “synergistic”, the sum of the FICs must be under 
0.5.  For the drugs tested, only Thai 18 under DHA and MFQ pressure had ∑FIC meeting 
this criteria when DHA and MFQ were in a 1:1 ratio of one another.  In order for a drug 
combination to be considered antagonistic, the FIC sum must be higher than 2 ng/ml  
Thai 6, when exposed to QHS and MFQ at a ratio of 1:3 respectively produced an ∑FIC 
of 2.320, which indicates a significant antagonistic effect.  In addition, Thai 6 treated 
with QHS and PIP in a ratio of 1:3 respectively also produced a significant antagonistic 
∑FIC of 2.048.  The W2 reference clone under similar conditions did not conclusively 
  
34 
 
lead to synergism or antagonism, which was expected from previous studies in the Kyle 
lab.  
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Table 1:  IC 50s (ng/ml) of Thai Isolates in the 72 hour SYBR Green Drug Assay 
 
 
  
ID 
number AM ART ATO DHA LF MFQ PIP QHS 
 
1.2 1.3 0.1 0.6 157.2 28.4 26.3 4.9 
3 1.1 1.2 0.3 0.5 42.4 7.8 8.3 3.9 
4 1.1 0.2 0.1 0.5 91.5 7.3 32.7 2.8 
5 0.2 0.1 0.1 0.5 32.5 2.3 4.6 1.2 
6 1.6 2.5 0.1 1.6 204.9 21.9 20.5 10.0 
8 0.5 1.0 0.1 0.9 46.2 4.0 23.2 1.9 
12 1.8 0.3 0.1 0.5 51.1 25.5 22.9 4.6 
13 0.5 0.2 0.2 0.4 209.1 5.7 8.6 1.6 
14 1.2 0.1 0.1 0.5 21.6 3.7 17.6 2.0 
16 2.3 0.9 5.1 0.9 3.4 3.4 9.2 5.1 
18 1.8 0.8 0.3 1.1 118.8 29.3 22.5 4.4 
20 1.5 0.7 0.2 0.6 55.3 5.5 23.0 3.7 
21 1.2 0.5 0.2 0.5 15.4 9.8 7.1 2.7 
22 0.7 0.3 0.2 0.4 35.9 15.2 2.5 1.4 
23 2.1 0.6 0.3 0.8 116.9 20.3 20.9 4.6 
24 1.3 0.5 0.2 0.5 53.3 8.2 36.0 3.6 
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Table 2:  IC 50s (ng/ml) of Cambodia isolates in the 72 hour SYBR Green 
Drug Assay 
 
 
 
 
 
ID AM AS ATO DHA LF MFQ PIP QHS 
                  
1 0.5 0.6 0.2 0.4 47.5 8.1 10.1 0.7 
3 0.9 0.9 0.2 0.5 68.6 15.7 17.2 1.5 
5 0.3 0.3 0.1 0.1 29.8 5.1 16.4 0.4 
6 3.1 2.1 0.2 1.5 113.6 56.0 12.4 6.1 
7 0.8 1.2 0.1 0.3 96.5 10.9 20.0 1.1 
8 1.4 1.0 0.2 0.8 25.9 8.9 15.5 2.7 
10 2.3 1.5 0.2 1.5 54.2 11.5 5.2 7.7 
13 1.1 0.3 0.1 1.7 28.1 4.2 52.3 3.1 
16 1.5 1.3 0.2 1.2 10.3 3.4 17.6 4.1 
21 0.8 1.4 0.1 2.0 15.6 2.4 66.4 6.6 
23 1.5 0.3 0.2 0.2 63.6 6.7 63.7 1.9 
25 0.6 0.1 0.1 0.1 11.7 2.2 18.5 1.1 
26 0.3 0.6 0.1 1.7 28.0 4.5 14.3 2.2 
27 0.6 0.1 0.1 0.2 14.2 2.0 6.8 1.2 
32 0.6 0.6 0.3 1.1 114.1 8.2 29.5 2.0 
33 1.1 0.1 0.1 0.7 5.4 0.8 4.7 1.9 
34 1.3 0.2 0.1 0.9 8.8 1.6 23.0 2.6 
42 1.0 0.1 0.2 0.3 13.9 1.9 19.8 1.6 
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Table 3:   IC 50s (ng/ml) of Reference Strains W2, D6 and C2B in the 72 
Hour SYBR Green Drug Assay 
 
  
control AM AS ATO DHA LF MFQ PIP QHS 
W2 .58 .56 .19 .61 6.11 3.78 28.12 1.48 
C2B 1.1 .01 62.5 .32 53.78 4.91 52.24 1.69 
D6 1.7 .19 .06 1.74 84.66 2.44 32.02 2.66 
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Discussion 
Findings 
This thesis describes the general resistance trends to 8 commonly used anti-
malarial drugs in recent P. falciparum isolates from Thailand and Cambodia.  It is 
important to determine if resistance is occurring early on, in order to devise an efficient 
containment plan, which can include, but is not limited to alteration of drug regiments, 
education, proper dispersal and formulation of new and improved drugs.  As 
hypothesized, results from this blinded phenotypic analysis show some trends that 
suggest isolates in Southeast Asia as less susceptible to some common ACT drugs. This 
is consistent with previous clinical and in vitro studies performed in the past (Noedl, 
2008; Khositnithikul, 2008).  
In particular, Cambodia isolate 6 and Thai isolate 6 were consistently less 
susceptible to the majority of drugs tested, in reference to the other isolates tested, as well 
as in comparison to the positive controls, C2b, D6 and W2 (refer to appendix B for 
details).  Atovaquone was the only drug to which all of the isolates (with the exception of 
Thai isolate 13) were consistently susceptible. Again, molecular markers testing should 
be conducted on Thai 13 in order to determine if a point mutation in Cytochrome B is 
indeed occurring, a key sign of atovaquone resistance ( Khositnithikul,2008). 
Drug combination assay studies revealed some unexpected trends towards 
antagonism for several ACT combinations.  An example of this was when Thai 6 was 
exposed to the 1 part QHS and 3 part MFQ drug combination (∑FIC=2.048), as well as 
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when exposed to the 3 QHS part and 1 part PIP drug combination (∑FIC=2.32).  Trends 
for some synergism in the drug combination responses were also observed with this 
assay, the most significant one being Thai 18 when incubated with 1 part DHA  to 1 part 
MFQ (∑FIC=.362). 
These blinded results should be validated via other methods.  The isolate data on 
drug susceptibility still needs to be tied back to original parasitemia and specific location 
to examine the trends more closely.  The results could be biased in that the majority of 
the isolates assayed may have originated from isolates with higher original parasite load.  
The isolates that did not grow successfully in the lab must be attempted to grow again so 
that one is not selecting and testing for a severe infection only.  Also, it is possible that 
these isolates already contained other types of drugs and although a thorough wash 
protocol was used, previous drug pressure could have also negatively affected the 
accuracy of our results when selecting for a particular drug. 
Strengths and Weaknesses  
The use of the SYBR Green assay has many advantages opposed to other 
conventional ways to evaluate drug effectiveness and ultimately drug resistance trends.  
For instance, lab personnel safety and clean up is a lot easier than a radioisotope assay. It 
is faster to carry out than an ELISA, which requires multiple washing steps, and the 
materials needed to complete the assay are easier to obtain.  Finally, the SYBR Green 
assay is more consistent and easier than the micro test (morphology based), which 
requires slides of each of the 96 well plates before a conclusion could be made (Bacon, 
2006).  Unfortunately, there are many variables in the assay that could negatively affect 
the accuracy of the results obtained.  For instance, slight alterations in parasite 
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parasitemia, hematocrit, and plasma lots could significantly alter IC50s obtained from all 
of the assay formats, including SYBR green.   
Testing drug combinations that have major structural and functional differences 
can also affect the accuracy of the data obtained.  For instance, if the improper ratio of 
drugs is used in a drug assay and one drug has a much different dose response profile, the 
∑FICs could become skewed.  Also, FICs can vary based on parasite strain and 
parasitemia, and since this is a blinded study, it is difficult to come to a solid conclusion 
regarding drug-drug interactions.  Further information and testing will need to be done in 
order to validate the assumptions made regarding the drug combinations. 
The data in the drug assays provide a phenotype that characterizes the drug 
response.  These phenotypes will be useful to identify putative genetic markers of 
resistance, such as SNPs or amplifications. If the mechanism of resistance is known for 
artemisinin and its derivatives, one can then test whether or not the same mechanism is 
occurring in a particular isolate of interest. 
Future study plans 
This study is the initial step in characterizing resistance trends in these particular 
isolates.  Data for these isolates will be compared to fresh, ex vivo in vitro drug 
susceptibility data conducted at the clinical field sites.  Isolates that did not successfully 
grow during this experiment will be attempted to be grown once again. Also, isolates 
showing decreased susceptibility to ACTs will also have further tests performed.  SNP 
studies, gene amplifications, as well as sequencing entire genomes to figure out resistance 
mechanisms will occur in the future at the University of Maryland.  Only then, will the 
real story of current ACT resistance be fully understood.  
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Appendix A 
 
 
 
 
 
Cambodia isolate 6 QHS(97) MFQ (99) 
 
 
 
 
 
 
 
Cambodia isolate 6 QHS(97) PIP (444)  
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Appendix A (continued) 
 
 
 
Thai isolate 6 QHS(97) MFQ (99)  
 
 
 
 
Thai 6 QHS(97) PIP(444)  
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Appendix A (continued) 
 
Thai 18 DHA (414) MFQ (99)  
 
 
 
 
 
 
Thai isolate 18  pip(444) DHA(414) 
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Appendix A (continued) 
 
W2 control QHS(97) PIP(444) 
 
 
 
 
 
 
W2 QHS (97) and MFQ (99) 
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Appendix A (continued) 
W2 DHA (414) PIP (444)  
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Appendix B continued 
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Appendix B continued 
 
 
 
  
 
 
 
 
 
53 
 
 
Appendix B continued 
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